advertisement
Schmelter C 18
Showing records 1 to 18 | Display only abstracts from Schmelter C in IGR 22-4106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Tonner H
International journal of molecular sciences 2022; 23: (IGR: 23-3)
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Fomo KN; Schmelter C
Frontiers in medicine 2022; 9: 993351 (IGR: 23-3)
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Hunn S
International journal of molecular sciences 2022; 23: (IGR: 23-3)
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Atta J
Frontiers in medicine 2022; 9: 993351 (IGR: 23-3)
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Auler N; Schmelter C
International journal of molecular sciences 2022; 23: (IGR: 23-3)
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Beutgen VM; Beutgen VM; Schwarz R
Frontiers in medicine 2022; 9: 993351 (IGR: 23-3)
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Pfeiffer N
International journal of molecular sciences 2022; 23: (IGR: 23-3)
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Perumal N
Frontiers in medicine 2022; 9: 993351 (IGR: 23-3)
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Grus FH
International journal of molecular sciences 2022; 23: (IGR: 23-3)
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Govind G; Speck T; Pfeiffer N; Grus FH
Frontiers in medicine 2022; 9: 993351 (IGR: 23-3)
100384 A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma
Tonner H; Hunn S; Auler N; Schmelter C; Beutgen VM; Beutgen VM; von Pein HD; Pfeiffer N; Grus FH
International journal of molecular sciences 2022; 23: (IGR: 23-1)
98949 Tear Film-specific Biomarkers in Glaucoma Patients
Fomo KN; Schmelter C; Pfeiffer N; Grus FH
Klinische Monatsblätter für Augenheilkunde 2022; 239: 165-168 (IGR: 22-4)
86807 Age related retinal Ganglion cell susceptibility in context of autophagy deficiency
Bell K; Rosignol I; Rosignol I; Sierra-Filardi E; Sierra-Filardi E; Rodriguez-Muela N; Schmelter C; Cecconi F; Grus F; Boya P
Cell death discovery 2020; 6: 21 (IGR: 21-2)
85168 Autoantigens in the trabecular meshwork and glaucoma-specific alterations in the natural autoantibody repertoire
Beutgen VM; Beutgen VM; Schmelter C; Pfeiffer N; Grus FH
Clinical & translational immunology 2020; 9: e01101 (IGR: 21-1)
82330 Comparative Quantitative Analysis of Porcine Optic Nerve Head and Retina Subproteomes
Funke S; Schmelter C; Markowitsch SD; Perumal N; Heyne JC; Bell K; Pfeiffer N; Grus FH
International journal of molecular sciences 2019; 20: (IGR: 20-4)
81118 An In-Depth View of the Porcine Trabecular Meshwork Proteome
Funke S; Beutgen VM; Beutgen VM; Bechter L; Schmelter C; Zurawski V; Perumal N; Pfeiffer N; Grus FH
International journal of molecular sciences 2019; 20: (IGR: 20-3)
75168 Peptides of the variable IgG domain as potential biomarker candidates in primary open-angle glaucoma (POAG)
Schmelter C; Perumal N; Funke S; Bell K; Pfeiffer N; Grus FH
Human Molecular Genetics 2017; 26: 4451-4464 (IGR: 19-2)
69347 Glaucoma related Proteomic Alterations in Human Retina Samples
Funke S; Perumal N; Beck S; Gabel-Scheurich S; Schmelter C; Teister J; Gerbig C; Gramlich OW; Pfeiffer N; Grus FH
Scientific reports 2016; 6: 29759 (IGR: 18-1)
